FOXO3 and neoplasm: Thus, silencing FOXO3a expression promotes carcinogenesis, progression, and unfavorable prognosis in gastric carcinoma (14), extrahepatic cholangiocarcinoma (15), pancreatic ductal adenocarcinoma (16), and clear cell renal cell carcinoma (6), suggesting its tumor-suppressor function.